Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial

Study limitation reported by the research below: “Retatrutide does not yet have FDA or EMA approval as of the paper's publication date; this is a phase 3 trial result.”